Pramiracetam.
The focus racetam. Long-lasting, no mood effects. A fat-soluble piracetam derivative studied for memory and attention. Its characterised action is raising high-affinity choline uptake, the transport step that feeds acetylcholine synthesis.
Reviewed March 2026
- Category
- Nootropic
- Also filed under
- FocusMemoryConcentration
What Pramiracetam is, and what it does.
- Does it work
- Suits people who know the racetam class and have checked its status where they live. It is a prescription medicine in several countries, so this one starts with a doctor.
- How much to take
- The band on record is 400 to 1,200mg a day, usually split in two. It is fat-soluble, so a dose with a meal containing fat behaves differently from one on an empty stomach.
- Time to feel it
- Within a few hours of a dose, and it tends to hold for much of the day. It is lipophilic, so taking it with fat changes how quickly it arrives.
- The first dose
- Something arrives within a few hours of the first dose and tends to hold across much of the day. Taken with fat, it turns up sooner.
- With regular use
- Each day rests on that day's dose rather than a reservoir that builds. Long-term daily data in healthy adults is thin, so nobody has measured what months of use look like.
- How well tolerated
- It is a prescription medicine in several countries and is not authorised as a food supplement everywhere it is sold. Check your local status and speak to a doctor first.
- How it feels
- People describe it as narrow and quiet: attention holds on one task, without the mood lift or edge a stimulant brings. Some report a headache when their choline supply runs short.
- The overlooked benefit
- It leans on your choline supply rather than supplying any, which is the reason it is usually paired with a choline source such as alpha-GPC or CDP-choline.
400 to 1,200mg a day is where Pramiracetam works.
Source: Mauri et al., 1994; McLean et al., 1991
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Based on 12 human trials with 55% consistency.
- Sodium-dependent high-affinity choline uptake in hippocampal tissueAnimal study
- Memory and recall measures in adultsRandomised trial
- Attention and information processing measuresRandomised trial
- Absence of meaningful affinity at classical neurotransmitter receptorsIn vitro study
Questions people ask about Pramiracetam.
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
- Any side effects to watch for?
- Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
- Who benefits most from this?
- Honestly, most people would benefit more from the basics. But if you've got a specific reason to try it, the risk is generally low.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Pramiracetam's defining action is raising high-affinity choline uptake at the nerve terminal, which pulls harder on the free choline pool than the other racetams do. Alpha-GPC refills that pool with choline that crosses the blood brain barrier.
Faster choline uptake only converts to acetylcholine if there is choline to take up. Running pramiracetam without a donor is the classic reason a dose leaves a heavy, dull head.
Phosphatidylcholine releases choline gradually as it is hydrolysed, matching the sustained uptake pramiracetam drives. It also contributes membrane phospholipid to the terminals doing the work.
Pramiracetam is fat soluble, so a lipid carrier in the same dose makes uptake more consistent than taking it dry on an empty stomach. This is a formulation effect rather than a pharmacological one.
Huperzine A slows acetylcholine breakdown while pramiracetam raises the uptake that feeds its synthesis. Both push the same signal, so the cholinergic effect is additive.
Choline is only half of acetylcholine, and acetyl-L-carnitine feeds the acetyl-CoA side of the reaction. Pairing it with a choline source covers both substrates pramiracetam's uptake step depends on.
Pramiracetam is a piracetam derivative with a stronger effect on choline uptake and no meaningful new mechanism. Stacking the two repeats one route and compounds the choline demand.
Acetylcholine synthesis is limited by choline availability at the presynaptic terminal, and choline acetyltransferase works on choline delivered by that high-affinity transporter. CDP-choline supplies both choline and cytidine, the latter feeding phosphatidylcholine synthesis through the Kennedy pathway. The pairing addresses supply for a mechanism that acts on uptake, which is the standard rationale for racetam plus choline donor combinations.
Phospholipases release choline from dietary phosphatidylcholine in the gut and in tissue, and that choline feeds both acetylcholine synthesis and membrane phospholipid turnover. This is textbook one-carbon and phospholipid biochemistry. It gives a slower-release choline supply than a free choline salt.
Soy or egg lecithin carries phosphatidylcholine alongside phosphatidylethanolamine and phosphatidylinositol, so it supplies choline plus other phospholipid headgroups used in membrane synthesis. The choline release step is enzymatic and well characterised. Choline content per gram is much lower than for a purified choline salt, which is the practical trade-off.
Choline acetyltransferase transfers an acetyl group from acetyl-CoA to choline, so acetylcholine synthesis needs both halves of the reaction present. Coenzyme A is built from pantothenate, cysteine and ATP in a five-step pathway. Supplying choline without regard to the acetyl side leaves half the substrate requirement unaddressed, which is why pantothenate belongs in this conversation.
Neuronal acetyl-CoA comes largely from glucose through pyruvate dehydrogenase, which cannot run without thiamine pyrophosphate. That places thiamine upstream of the acetyl group in every acetylcholine molecule. Established enzymology, no trial required.
Neuronal membranes concentrate DHA at the sn-2 position of phosphatidylethanolamine and phosphatidylcholine, and membrane composition affects receptor and transporter behaviour. Choline supplies the headgroup, DHA the acyl chain. They contribute different parts of the same molecule rather than competing.
Phosphatidylserine is synthesised by base exchange from phosphatidylcholine or phosphatidylethanolamine, so the three headgroups interconvert. Supplying serine-headed phospholipid alongside choline-headed phospholipid feeds the same interconverting pool. The pairing is common in cognitive formulas without a combination trial behind it.
Bacosides are the studied constituents and their described actions in preclinical work involve antioxidant and cholinergic signalling by different routes than a racetam's effect on choline transport. The stack is a formulation convention. There is no measured combination data.
Ginkgo's characterised constituents affect platelet activating factor signalling and vascular tone, a separate axis from cholinergic precursor supply. That makes the pairing complementary in intent and not overlapping in mechanism. It also means the ginkgo-specific caution about additive effects on normal clotting travels with the stack.
Caffeine acts by competitive antagonism at adenosine A1 and A2A receptors, which is settled pharmacology and unrelated to choline transport. The stack combines two independent mechanisms rather than reinforcing one. Stimulant load and its effect on sleep is the limit that applies.
Theanine is structurally close to glutamate and interacts with glutamate transporters and receptors at low affinity, with human EEG work reporting shifts in alpha activity, a marker. Its usual role in a stack is to smooth stimulation rather than to add to it. No combination trial with a racetam exists.
Tyrosine hydroxylase converts tyrosine to L-DOPA, the rate-limiting step in catecholamine synthesis, and substrate supply matters most when catecholamine turnover is high. That axis is separate from the cholinergic one a racetam touches. Two precursor pools, two pathways.
ATP functions biologically as a magnesium complex, so every kinase step in choline phosphorylation and coenzyme A assembly depends on magnesium availability. It also modulates NMDA receptor conductance as a voltage-dependent channel blocker. Basic enzymology rather than a specific interaction with this compound.
Nothing specific on file for Pramiracetam. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Pramiracetam actually does.
Pramiracetam is a piracetam derivative in which the acetamide of piracetam is replaced by a diisopropylaminoethyl amide, a change that makes the molecule considerably more lipophilic than the parent compound.
Because the molecule is lipophilic, its dissolution and absorption depend on the presence of lipid, and a dose taken with fat behaves differently from the same dose taken on an empty stomach.
Pramiracetam is regulated as a prescription medicine in several countries and is not authorised as a food supplement everywhere it is sold, so its regulatory standing differs by jurisdiction from that of a nutrient.
Its characterised preclinical action is an increase in sodium-dependent high-affinity choline uptake in hippocampal tissue, an effect on the transport step that feeds acetylcholine synthesis rather than direct binding at a cholinergic receptor.
Where Pramiracetam comes from.
There is no plant or animal involved. Chemists start from a simple ring-shaped industrial chemical, attach an acid arm to it, then join that arm to a fatty side piece. The result is crystallised, tested for purity, and either put straight into capsules or mixed into oil first.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
The pyrrolidinone ring system that defines the racetam class is built from petrochemical-derived 2-pyrrolidinone, alkylated at nitrogen with a haloacetate ester or acid.
The N-alkylated ring is hydrolysed to 2-oxo-1-pyrrolidineacetic acid, the shared acid intermediate of the class and the compound's own main metabolite.
The acid is activated, usually as an ester or acyl derivative, and coupled with N,N-diisopropylethylenediamine to install the lipophilic amide side chain that distinguishes pramiracetam from piracetam.
The crude amide is washed and recrystallised to remove unreacted amine, the acid intermediate and process solvents, with residual solvent limits set by pharmacopoeial method.
Identity is confirmed spectroscopically and purity by HPLC against a reference standard, with the related-substance profile reported.
The assayed solid is encapsulated dry, or dispersed in a lipid carrier before softgel filling.
Certificates of analysis for this compound vary in whether they report the related-substance profile and residual solvents at all, and the manufacturing country is often not stated, both of which matter more here than for a nutrient because the whole molecule is a process output.
Getting Pramiracetam from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
Problems people have reported.
Read this carefully. These are 53 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Pramiracetam is, not how risky it is. A report is not proof Pramiracetam caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.